

MARINOMED BIOTECH AG

ISIN: ATMARINOMED6 WKN: - Asset Class: Stock

Company

2024/04/19 17:35:16



Price

19.40

EUR

Difference

-3.00% (-0.60)

Contact Details

MARINOMED BIOTECH AG Tel: +43-1-2262-90300
 -- Fax: +43-1-25077-4493
 Hovengasse 25 Web: <http://www.marinomed.com>
 2100 Korneuburg E-mail: -



Company Profile

Marinomed Biotech AG is a biopharmaceutical company, which engages in the development of therapies based on patent protected technology platforms. It operates through the following segments: Immunology, Virology, and Other. The company was founded by Andreas Grassauer and Eva Prieschl-Grassauer in 2006 and is headquartered in Korneuburg, Austria.

Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2023		2022		2021	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	7,135,000	-	14,267,000	-	12,877,000	-
Common stock capital	-	-	-	1,506,000	-	1,480,000
Fixed assets	7,476,000	-	8,019,000	-	8,459,000	-
Equity capital of a company	-	-10,136,000	-	-4,157,000	-	191,000
Cash and cash equivalents	2,588,000	-	8,175,000	-	5,802,000	-
Accrued liabilities	-	0	-	0	-	0
Other assets	-	-	-	-	-	-
Current liabilities	-	9,653,000	-	5,956,000	-	6,013,000
Prepayments and accrued income	-	-	-	-	-	-
Non-current liabilities	-	15,094,000	-	20,487,000	-	15,131,000
Different income	-	-	-	-	-	-
Other liabilities	-	254,000	-	304,000	-	87,000
Total assets	14,611,000	14,611,000	22,286,000	22,286,000	21,337,000	21,337,000

Balance notes

	2023	2022	2021
Accounting standard	IFRS	IFRS	IFRS
Employees	-	49	47
Equity ratio	-69.37%	-18.65%	0.90%
Debt-equity ratio	-244.15%	-636.11%	11,047.86%

Others

	2023	2022	2021
Tax Expense Rate	-0.06%	-0.11%	-3.46%

MARINOMED BIOTECH AG

ISIN: ATMARINOMED6 WKN: - Asset Class: **Stock**

Income statement

	2023	2022	2021
Turnover	9,183,000	11,275,000	11,627,000
Net income	-6,794,000	-6,397,000	-5,891,000
EBIT	-6,790,800	-3,882,900	-4,185,100
Operating income before taxes	-6,790,000	-6,390,000	-5,694,000
Cash Flow	-4,528,000	-5,202,000	-4,866,000
Net interest income	-	-2,508,000	-1,509,000
Research and development expenses	-	6,905,000	7,504,000
Income taxes	4,000	6,000	197,000
Result from investments in subsidiaries, associates and other	0	0	0
Revenues per employee	-	230,120	247,400

Board of Directors

Simon Nebel	Chairman of Supervisory Board
Elisabeth Lackner	Member of Supervisory Board
Eva Hofstädter-Thalmann	Member of Supervisory Board
Brigitte Ederer	Member of Supervisory Board
Ulrich Kinzel	Member of Supervisory Board

Members of Management Board

Andreas Grassauer	Chairman of Managing Board
Eva Prieschl-Grassauer	Member of Executive Committee
Pascal Schmidt	Member of Executive Committee